Wednesday, April 17, 2013

Tudor Reilly – revolutionizing clinical trial recruitment

Today's guest post is from Peter Coë, the Executive Director and Co-Founder of Tudor Reilly.  They are a sponsor of this year's Partnerships in Clinical Trials event and will be at Booth 206.  If you'd like to join them, as a reader of this blog, when you register to join us and mention code XP1800BLOG, you'll save 15% off the standard rate!

Although clinical trials are on the increase, public awareness of how to take part in medical research remains limited. In fact, just 30% of patients are aware of the traditional ports of call for clinical trials such as clinicaltrials.gov. Strict regulation and a lack of general education are two reasons for this, but the willingness of many pharma sponsors and CROs to stick with traditional methods of patient recruitment also plays a part.

This situation has a significant impact on the pharmaceutical industry. Around 90% of clinical trials are extended by at least six weeks due to failure to enroll patients on schedule. And, delays in bringing a drug to market can cost a pharmaceutical company as much as $8 million a day.

At Tudor Reilly, we specialise in what we call e-patient recruitment – enabling, empowering and engaging patients with accessible and relevant information on specific health conditions, and on clinical trials, that the e-patient and their families can find and understand. We do this by building and nurturing online patient communities and by providing high-quality content that’s relevant, current and useful.


See our innovative approach to e-patient recruitment in action by visiting the Tudor Reilly team at stand 206. You’ll also have the chance to win an iPad in our exclusive e-patient recruitment challenge. And don’t miss our executive director and co-founder Peter Coë’s talk on building therapeutic communities online on Monday at 4:15pm, as part of his introduction to keynote speaker Deborah W Brooks from The Michael J Fox Foundation for Parkinson’s Research.




No comments: